Raben David 4

4 · Bicara Therapeutics Inc. · Filed Mar 26, 2026

AI-generated summary of this filing

Updated Mar 26, 2026

Bicara (BCAX) CMO David Raben Sells 5,500 Shares After Option Exercise

What Happened

David Raben, Chief Medical Officer of Bicara Therapeutics (BCAX), exercised stock options and sold the resulting shares on March 25, 2026. The filing shows an acquisition of 5,500 shares via option exercise at $3.79/share (total cost $20,844) and a contemporaneous open-market sale of 5,500 shares at a weighted average price of $18.95/share (gross proceeds $104,229). A related derivative conversion line for 5,500 shares is also reported at $0.00. The transaction is a sale (often routine) following an option exercise.

Key Details

Transaction date: 2026-03-25; filing date: 2026-03-26 (timely).
Option exercise: 5,500 shares acquired at $3.79 each = $20,844.
Open-market sale: 5,500 shares sold at weighted avg $18.95 each = $104,229.
Reported derivative line: 5,500 shares, $0.00 (as reported in the filing).
Footnote F1: Sale executed pursuant to a Rule 10b5-1 trading plan adopted Feb 12, 2025.
Footnote F2: Weighted-average sale price; actual sale prices ranged $18.55–$19.36. Reporting person will provide per-price detail on request.
Footnote F3: Underlying option vests in 16 equal quarterly installments beginning Aug 8, 2023.
Shares owned after the transaction: not disclosed in the provided filing.

Context

The sequence (exercise of options and same-day sale) is commonly used to cover the exercise cost and tax obligations; it results in a realized gain (sale proceeds minus exercise cost). This filing is factual and routine; it does not indicate the insider's broader view of the company.

Form 4

Period: 2026-03-25

Chief Medical Officer

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-03-25$3.79/sh+5,500$20,844→ 60,786 total
Sale
Common Stock
[F1][F2]
2026-03-25$18.95/sh−5,500$104,229→ 55,286 total
Exercise/Conversion
Stock Option (Right to Buy)
[F1][F3]
2026-03-25−5,500→ 47,413 total
Exercise: $3.79Exp: 2023-08-08→ Common Stock (5,500 underlying)

Footnotes (3)

[F1]This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025.
[F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.55 to $19.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
[F3]The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date.

Signature

/s/ Lara Meisner, Attorney-in-Fact|2026-03-26

1 file